Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Electric fields and radiation team up against pancreas cancer

NCT ID NCT05679674

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times

Summary

This study tests whether adding a device that sends low-intensity electric fields (tumor treating fields) to standard radiation therapy can slow tumor growth in people with locally advanced pancreas cancer. About 48 participants will receive radiation for 5 days and use the device at least 18 hours daily until their disease worsens. The goal is to see if this combination improves how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Miami Cancer Institute at Baptist Health, Inc.

    RECRUITING

    Miami, Florida, 33176, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Stereotactic ablative body radiation (SABR) and tumor treating fields (TTF) device

What this could lead to

If successful, this combination could slow tumor growth and extend survival for people with locally advanced pancreas cancer.

What could go wrong

This is a small early-phase trial with only 48 participants, so results may not apply widely. The TTF device must be worn 18+ hours daily, which may be burdensome, and side effects from radiation or the device could occur.

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.